Should I buy or sell Zai Lab stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ZLAB shares. View ZLAB analyst ratings or view top-rated stocks .

What is Zai Lab's stock price target for 2024?

5 brokerages have issued twelve-month target prices for Zai Lab's stock. Their ZLAB share price targets range from $47.50 to $73.34. On average, they anticipate the company's stock price to reach $64.22 in the next year. This suggests a possible upside of 345.4% from the stock's current price. View analysts price targets for ZLAB or view top-rated stocks among Wall Street analysts .

How have ZLAB shares performed in 2024?

Zai Lab's stock was trading at $27.33 at the beginning of 2024. Since then, ZLAB stock has decreased by 47.2% and is now trading at $14.42. View the best growth stocks for 2024 here .

When is Zai Lab's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our ZLAB earnings forecast .

How can I listen to Zai Lab's earnings call?

Zai Lab will be holding an earnings conference call on Thursday, May 9th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link .

How were Zai Lab's earnings last quarter?

Zai Lab Limited (NASDAQ:ZLAB) posted its earnings results on Tuesday, February, 27th. The company reported ($0.98) earnings per share for the quarter, missing analysts' consensus estimates of ($0.87) by $0.11. The firm had revenue of $65.83 million for the quarter, compared to analyst estimates of $70.41 million. Zai Lab had a negative trailing twelve-month return on equity of 37.07% and a negative net margin of 125.46%.

What ETFs hold Zai Lab's stock?

ETFs with the largest weight of Zai Lab (NASDAQ:ZLAB) stock in their portfolio include Global X China Biotech Innovation ETF (CHB) , Amplify Treatments, Testing and Advancements ETF (GERM) , Virtus LifeSci Biotech Products ETF (BBP) , Loncar China Biopharma ETF (CHNA) and ALPS Medical Breakthroughs ETF (SBIO) . Invesco Golden Dragon China ETF (PGJ) .

What other stocks do shareholders of Zai Lab own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include NVIDIA (NVDA) , CRISPR Therapeutics (CRSP) , Inseego (INSG) , Niu Technologies (NIU) , JD.com (JD) , Bilibili (BILI) , Marvell Technology (MRVL) , Baidu (BIDU) , BioXcel Therapeutics (BTAI) and Baozun (BZUN) .

When did Zai Lab IPO?

Zai Lab (ZLAB) raised $100 million in an IPO on Wednesday, September 20th 2017. The company issued 5,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners acted as the underwriters for the IPO.

How do I buy shares of Zai Lab?

Shares of ZLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ZLAB

Zai Lab (ZLAB) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free ZLAB Stock Alerts

$14.42

+0.22 (+1.55%)

(As of 04/16/2024 ET)

Compare

Today's Range: $14.01
▼
$14.67
50-Day Range: $14.20
▼
$22.49
52-Week Range: $14.01
▼
$39.50

Volume: 400,722 shs
Average Volume: 644,444 shs
Market Capitalization: $1.43 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $64.22

Get Zai Lab alerts:

Zai Lab MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 345.4% Upside
$64.22 Price Target
Short Interest: Bearish
3.90% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.49
Based on 6 Articles This Week
Insider Trading: Selling Shares
$208,508 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($3.10) to ($1.78) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.93 out of 5 stars

Medical Sector

614th out of 930 stocks

Pharmaceutical Preparations Industry

281st out of 420 stocks

3.5

Analyst's Opinion

Consensus Rating
Zai Lab has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Zai Lab has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
3.90% of the outstanding shares of Zai Lab have been sold short.
Short Interest Ratio / Days to Cover
Zai Lab has a short interest ratio ("days to cover") of 5.8.
Change versus previous month
Short interest in Zai Lab has recently increased by 5.74%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Zai Lab does not currently pay a dividend.
Dividend Growth
Zai Lab does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ZLAB.

2.5

News and Social Media Coverage

News Sentiment
Zai Lab has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Zai Lab this week, compared to 4 articles on an average week.
Search Interest
9 people have searched for ZLAB on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Zai Lab to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Zai Lab insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $208,508.00 in company stock.
Percentage Held by Insiders
Only 5.23% of the stock of Zai Lab is held by insiders.
Percentage Held by Institutions
41.65% of the stock of Zai Lab is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Zai Lab are expected to grow in the coming year, from ($3.10) to ($1.78) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Zai Lab is -4.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Zai Lab is -4.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Zai Lab has a P/B Ratio of 1.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Manward Press

Can't believe it's happening again

One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.

We explain how this event works in full right here.

About Zai Lab Stock (NASDAQ:ZLAB)

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

ZLAB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ZLAB Stock News Headlines

April 6, 2024 | insidertrades.com

Zai Lab Limited (NASDAQ:ZLAB) CFO Sells $13,241.15 in Stock

April 4, 2024 | insidertrades.com

Frazor Titus Edmondson III Sells 885 Shares of Zai Lab Limited (NASDAQ:ZLAB) Stock

April 16, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

March 20, 2024 | insidertrades.com

Rafael Amado Sells 2,544 Shares of Zai Lab Limited (NASDAQ:ZLAB) Stock

April 15, 2024 | businesswire.com

Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024

April 15, 2024 | businesswire.com

Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024

April 11, 2024 | finance.yahoo.com

Zai Lab Statement on Executive Management Team’s Agreement on Share Activities

April 11, 2024 | businesswire.com

Zai Lab Statement on Executive Management Team's Agreement on Share Activities

April 16, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

April 9, 2024 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Zai Lab (ZLAB) and Idexx Laboratories (IDXX)

April 7, 2024 | americanbankingnews.com

Yajing Chen Sells 845 Shares of Zai Lab Limited (NASDAQ:ZLAB) Stock

April 7, 2024 | americanbankingnews.com

Joshua L. Smiley Sells 1,988 Shares of Zai Lab Limited (NASDAQ:ZLAB) Stock

April 2, 2024 | businesswire.com

Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs

April 1, 2024 | msn.com

Zai Lab reports Krazati lung cancer study meets primary endpoint

April 1, 2024 | finance.yahoo.com

Shareholders in Zai Lab (NASDAQ:ZLAB) are in the red if they invested three years ago

April 1, 2024 | msn.com

One Good, One Bad News For Bristol Myers Squibb's Marketed Drugs: Details

April 1, 2024 | finance.yahoo.com

Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...

March 27, 2024 | msn.com

Novocure climbs after late-stage win for lung cancer therapy

March 27, 2024 | businesswire.com

Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

March 26, 2024 | finance.yahoo.com

ZLAB Sep 2024 17.500 call

March 26, 2024 | finance.yahoo.com

ZLAB Jan 2025 20.000 call

March 21, 2024 | investing.com

Zai Lab's chief legal officer sells shares worth over $187,000

March 20, 2024 | investorplace.com

Shhh! 7 Small-Cap Stocks That Can Double by 2025

March 19, 2024 | finance.yahoo.com

Chief Legal Officer Edmondson Frazor Titus III Sells 10,000 Shares of Zai Lab Ltd (ZLAB)

March 17, 2024 | finance.yahoo.com

ZLAB Apr 2024 12.500 put

March 17, 2024 | finance.yahoo.com

ZLAB Apr 2024 25.000 call

March 16, 2024 | finance.yahoo.com

ZLAB Apr 2024 17.500 call

See More Headlines

Receive ZLAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zai Lab and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/27/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ZLAB
CUSIP: N/A
CIK: 1704292
Web: www.zailaboratory.com
Phone: 862161632588
Fax: 86-21-6163-2570
Employees: 2,175
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $64.22
High Stock Price Target: $73.34
Low Stock Price Target: $47.50
Potential Upside/Downside: +352.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.45)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-334,620,000.00
Net Margins: -125.46%
Pretax Margin: -125.46%
Return on Equity: -37.07%
Return on Assets: -30.72%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.63
Quick Ratio: 4.41

Sales & Book Value

Annual Sales: $266.72 million
Price / Sales: 5.28
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $8.05 per share
Price / Book: 1.76

Miscellaneous

Outstanding Shares: 99,210,000
Free Float: 94,020,000
Market Cap: $1.41 billion
Optionable: Optionable
Beta: 1.10

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Dr. Ying Du Ph.D. (Age 58)
Founder, Chairperson & CEO
Comp: $1.67M
Mr. Joshua L. Smiley (Age 54)
President & COO
Comp: $647.11k
Dr. Rafael G. Amado M.D. (Age 60)
President and Head of Global Oncology Research & Development
Comp: $477k
Dr. Harald Reinhart M.D. (Age 72)
President and Head of Global Development for Neuroscience, Autoimmune & Infectious Diseases
Comp: $923.33k
Dr. Yajing Chen Ph.D.
Chief Financial Officer
Dr. Peter Huang Ph.D.
Chief Scientific Officer
Ms. Christine Chiou
Senior VP & Head of Investor Relations
Mr. Frazor Titus Edmondson III (Age 58)
J.D., Chief Legal Officer & Corporate Secretary
Comp: $829k
Ms. Ann E. Beasley J.D.
Chief Compliance Officer
Dr. Ning Xu M.D. (Age 59)
Executive VP & Head of Clinical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ZLAB Stock Analysis - Frequently Asked Questions

Should I buy or sell Zai Lab stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ZLAB shares.
View ZLAB analyst ratings or view top-rated stocks.
What is Zai Lab's stock price target for 2024?: 5 brokerages have issued twelve-month target prices for Zai Lab's stock. Their ZLAB share price targets range from $47.50 to $73.34. On average, they anticipate the company's stock price to reach $64.22 in the next year. This suggests a possible upside of 345.4% from the stock's current price.
View analysts price targets for ZLAB or view top-rated stocks among Wall Street analysts.
How have ZLAB shares performed in 2024?: Zai Lab's stock was trading at $27.33 at the beginning of 2024. Since then, ZLAB stock has decreased by 47.2% and is now trading at $14.42.
View the best growth stocks for 2024 here.
When is Zai Lab's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our ZLAB earnings forecast.
How can I listen to Zai Lab's earnings call?: Zai Lab will be holding an earnings conference call on Thursday, May 9th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.
How were Zai Lab's earnings last quarter?: Zai Lab Limited (NASDAQ:ZLAB) posted its earnings results on Tuesday, February, 27th. The company reported ($0.98) earnings per share for the quarter, missing analysts' consensus estimates of ($0.87) by $0.11. The firm had revenue of $65.83 million for the quarter, compared to analyst estimates of $70.41 million. Zai Lab had a negative trailing twelve-month return on equity of 37.07% and a negative net margin of 125.46%.

What ETFs hold Zai Lab's stock?: ETFs with the largest weight of Zai Lab (NASDAQ:ZLAB) stock in their portfolio include Global X China Biotech Innovation ETF (CHB), Amplify Treatments, Testing and Advancements ETF (GERM), Virtus LifeSci Biotech Products ETF (BBP), Loncar China Biopharma ETF (CHNA) and ALPS Medical Breakthroughs ETF (SBIO).Invesco Golden Dragon China ETF (PGJ).
What other stocks do shareholders of Zai Lab own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), Niu Technologies (NIU), JD.com (JD), Bilibili (BILI), Marvell Technology (MRVL), Baidu (BIDU), BioXcel Therapeutics (BTAI) and Baozun (BZUN).
When did Zai Lab IPO?: Zai Lab (ZLAB) raised $100 million in an IPO on Wednesday, September 20th 2017. The company issued 5,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners acted as the underwriters for the IPO.
How do I buy shares of Zai Lab?: Shares of ZLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ZLAB) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial